Discovery, Characterisation, & Optimisation of CBP Selective Degraders
Time: 8:45 am
day: Conference Day One
Details:
- Identifying and optimizing potent, selective degraders of CBP to address mutant EP300 Cancers
- Spotlighting demonstrated, robust activity in preclinical pk/pd and efficacy models
- Demonstrating no observed thrombocytopenia in mice at pharmacologically relevant doses
